Pfizer enters new discovery and licensing deal with Enodia for Sec61 inhibitor candidates

Pfizer has signed a new drug discovery collaboration and license agreement with Enodia Therapeutics focused on developing Sec61 inhibitors, according to a report published by Yahoo Finance on Oct. 21, 2026.

Sec61 (also known as the SEC61 translocon) is a protein channel involved in moving newly made proteins across cell membranes. Sec61 inhibitors are designed to block that process, which is an approach being explored across oncology and other disease areas where protein handling and cellular stress pathways are thought to matter. In the deal described by the report, Enodia is advancing small-molecule “Sec61 blockers” intended to interfere with the target.

Under the arrangement, Pfizer and Enodia would work together on discovery and development of these candidates, with licensing elements included in the agreement. A “license” in this context generally means Pfizer would obtain rights to use, develop, or commercialize resulting intellectual property or drug candidates, though the scope and timing are not described in the reported announcement.

The report does not provide financial terms, including upfront payments, milestone levels, or royalty rates. It also does not specify whether Pfizer and Enodia will split responsibilities by therapeutic area, trial phase, or geography. Neither the reported materials nor additional official detail were available in the materials provided for this write-up.

For Pfizer, partnering on preclinical or early discovery work is a way to broaden its research pipeline while managing the cost and risk of bringing new mechanisms of action to the clinic. Deals like this can also give large pharmaceutical companies access to specialized scientific programs and screening or chemistry platforms.

For Enodia, collaboration with a major drugmaker can help translate early-stage biology into a larger development plan, including the possibility of advancing candidates through later-stage studies if milestones are met. The Sec61 inhibitor concept is still a specialized space, so external validation via a licensing-backed research agreement can be a meaningful step for smaller biotechs.

Still, key specifics remain unclear. The reported account does not identify which indications Pfizer intends to pursue first, the status of Enodia’s lead Sec61 inhibitor program at the time of signing, or the timeline for candidate selection, preclinical proof, or first-in-human studies.

Investors and industry watchers will likely focus next on any subsequent disclosures from Pfizer or Enodia that outline development responsibilities, candidate timelines, and whether the companies plan to progress particular lead molecules into formal preclinical packages or clinical trial applications.